Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 14/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 11/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414719 | 0.94 | ITGA4 (0.40) | ITGA4ITGB1GPBAR1CHRM3ACKR3 | |
| SCHEMBL5162765 | 0.89 | ITGA4 (0.40) | ITGA4ITGB1CHRM3TP53THRB | |
| SCHEMBL5160960 | 0.88 | ITGB1 (0.54) | ITGA4ITGB1CHRM3ACKR3 | |
| SCHEMBL5162198 | 0.84 | ITGA4 (0.37) | ITGA4ITGB1GPBAR1ACKR3TP53 | |
| SCHEMBL5160982 | 0.84 | ITGA4 (0.39) | ITGA4ITGB1GPBAR1CHRM3ACKR3 | |
| SCHEMBL5160816 | 0.83 | ITGB1 (0.40) | ITGA4ITGB1CHRM3TP53 | |
| SCHEMBL5176215 | 0.83 | ITGB1 (0.52) | ITGA4ITGB1CHRM3 | |
| SCHEMBL5160701 | 0.83 | ITGB1 (0.47) | ITGA4ITGB1ACKR3PTGDR2 | |
| SCHEMBL14371618 | 0.79 | ITGA4 (0.41) | ITGA4ITGB1 | |
| SCHEMBL5162846 | 0.79 | ITGA4 (0.37) | ITGA4ITGB1GPBAR1ACKR3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ITGA4 3/4885ITGB1 9/4885GPBAR1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.